A CANNABIS-BASED medicine can now be prescribed to sufferers of a rare genetic condition which causes seizures as part of a raft of drugs approved for use on the Scottish health service.
Epidyolex, or cannabidiol, was approved by the Scottish Medicines Consortium (SMC) on Monday for use on patients as young as two years old with seizures associated with tuberous sclerosis complex, a rare genetic condition which requires round the clock care and impacts on all aspects of life.
Consortium chair, Mark MacGregor, said: “For people living with tuberous sclerosis complex, cannabidiol may reduce the number of seizures experienced each day, leading to marked improvements in quality of life for both patients and their carers.”
The consortium has also approved five other drugs for use on the Scottish NHS, including Ontozry, or cenobamate, as a treatment of epileptic seizures.
READ MORE: ‘Police treated me like I was a criminal’: Legal cannabis user left suicidal
And Enzalutamide, or Xtandi, can now be prescribed to men with prostate cancer which has spread to other parts of the body.
Amy Rylance, head of improving care at Prostate Cancer UK, described it as “fantastic news for hundreds of men in Scotland with advanced prostate cancer, particularly those who may not be able to have chemotherapy”.
“New hormonal treatments like enzalutamide are just as effective as chemotherapy but cause far fewer side-effects, which is why we’ve been working hard to make them permanently available to men,” she said.
“We’re delighted that men in Scotland will now be able to choose the treatment that is right for them and gain precious additional time with their loved ones.”
Other drugs which have been given the go-ahead to be prescribed to patients in Scotland include one for use in people with a rare lung cancer caused by exposure to asbestos.
READ MORE: How legal medical cannabis patients are being forced onto illicit drugs market
Nivolumab, or Opdivo, was accepted for the treatment of advanced malignant pleural mesothelioma, a type of lung cancer that affects the thin membrane that lines the lungs.
The drug gives disease sufferers four months longer, on average, than conventional chemotherapy, and patients with the cancer told the SMC of the importance of the extra time with theie loved ones.
Other medicines approved by the consortium include Risdiplam, or Evrysdi, for the treatment of rare muscle wasting disease spinal muscular atrophy, and Pemigatinib, or Pemazyre, for the treatment of advanced cholangiocarcinoma, a cancer of the bile ducts in patients with a specific gene mutation.
MacGregor said: “Cholangiocarcinoma is a rare form of bile duct cancer with very few effective treatment options. Pemigatinib offers a more personalised treatment and can be taken at home giving patients more quality time to spend with family.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here